| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

22 June 2023

MidCap Paris 2023

Paris

France

7-9 June 2023

Jefferies Healthcare Conference 2023

New York

NY

United States

5-8 June 2023

BIO International Conference 2023

Boston Convention & Exhibition Center in Boston

MA

United States

31 May - 1 June 2023

VI Ibero-American Congress CEAPI 2023

Madrid

Spain

30 May - 1 June 2023

Foro Medcap BME 2023

Palacio de la Bolsa

Madrid

Spain

14-23 May 2023

BioEquity Europe 2023

Spencer Dock, Dublin

Ireland

9 May 2023

ORYZON to give updates on corporate progress in May-June

3 April 2023

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

15 March 2023

ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/refractory FLT3-mutant acute myeloid leukemia patients

13 March 2023

ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disorders

Pagination

First page «
Previous page ‹
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel